TY - JOUR
T1 - Managing Disability in Progressive Multiple Sclerosis
AU - Dubey, Divyanshu
AU - Sguigna, Peter
AU - Stüve, Olaf
N1 - Funding Information:
Olaf Stüve serves on the editorial boards of JAMA Neurology, Multiple Sclerosis Journal, and Therapeutic Advances in Neurological Disorders. Dr. Stüve has served on data monitoring committees for Pfizer and Sanofi-Aventis without monetary compensation, represented Novartis in front of a Scientific Advisory Group at the European Medicines Agency (EMA), and has advised Genentech and Sanofi-Aventis. Dr. Stüve currently receives grant support from Teva Pharmaceuticals and Opexa Therapeutics, has received travel support from Pfizer, and is funded by a Merit grant from the US Department of Veterans Affairs.
Publisher Copyright:
© 2016, Springer Science+Business Media New York (outside the USA).
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Patients with progressive forms of multiple sclerosis have various symptoms which affect their quality of life significantly including depression, cognitive decline, sleep changes, bladder dysfunction, sexual dysfunction, and spasticity. Despite recent promising results on the effects of ocrelizumab on neurological disability in patients with PPMS, currently none of the immunomodulatory therapies are approved for progressive forms of multiple sclerosis. Therefore, clinicians currently mostly focus on management of well-recognized comorbidities of this disease phenotype in order to improve patients’ quality of life. There are very few studies evaluating strategies of symptomatic management on progressive forms of multiple sclerosis and most of the data is derived from studies on relapsing forms of multiple sclerosis. Understanding of the risks, benefits, and limitations of these therapies can significantly affect patient care. In this article, we review common comorbidities associated with progressive forms of multiple sclerosis and outline important strategies for their symptomatic management.
AB - Patients with progressive forms of multiple sclerosis have various symptoms which affect their quality of life significantly including depression, cognitive decline, sleep changes, bladder dysfunction, sexual dysfunction, and spasticity. Despite recent promising results on the effects of ocrelizumab on neurological disability in patients with PPMS, currently none of the immunomodulatory therapies are approved for progressive forms of multiple sclerosis. Therefore, clinicians currently mostly focus on management of well-recognized comorbidities of this disease phenotype in order to improve patients’ quality of life. There are very few studies evaluating strategies of symptomatic management on progressive forms of multiple sclerosis and most of the data is derived from studies on relapsing forms of multiple sclerosis. Understanding of the risks, benefits, and limitations of these therapies can significantly affect patient care. In this article, we review common comorbidities associated with progressive forms of multiple sclerosis and outline important strategies for their symptomatic management.
KW - Depression
KW - Gait disorder
KW - Incontinence
KW - Neuropsychiatric manifestations
KW - Primary progressive multiple sclerosis
KW - Secondary progressive multiple sclerosis
KW - Sexual dysfunction
KW - Spasticity
UR - http://www.scopus.com/inward/record.url?scp=84963787573&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963787573&partnerID=8YFLogxK
U2 - 10.1007/s11940-016-0412-7
DO - 10.1007/s11940-016-0412-7
M3 - Review article
C2 - 27089873
AN - SCOPUS:84963787573
SN - 1092-8480
VL - 18
JO - Current Treatment Options in Neurology
JF - Current Treatment Options in Neurology
IS - 6
M1 - 27
ER -